Cardiovascular risk factor control is insufficient in young patients with coronary artery disease

Vascular Health and Risk Management

Volumn 12, Issue , 2016, Pages 219-227

  Christiansen, Morten Krogh ^a   Jensen, Jesper Møller ^a   Brøndberg, Anders Krogh ^a   Bøtker, Hans Erik ^a   Jensen, Henrik Kjærulf ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular diseases prevention and control; Coronary artery disease; Health behavior; Middle aged; Risk factors; Young adult

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; RISK MANAGEMENT; SMOKING; THROMBOSIS; YOUNG ADULT; ADVERSE EFFECTS; BLOOD; BLOOD PRESSURE; BODY MASS; DENMARK; DRUG EFFECTS; DYSLIPIDEMIAS; EXERCISE; MIDDLE AGED; ONSET AGE; OVERWEIGHT; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES; REGISTER; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; TIME FACTOR; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

ADULT; AGE OF ONSET; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DENMARK; DYSLIPIDEMIAS; EXERCISE; FEMALE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LIPASE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; PREVALENCE; REGISTRIES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; TIME FACTORS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 84969920214     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S106436     Document Type: Article

References (25)

1. Schoenenberger AW, Radovanovic D, Stauffer J-C, et al. AMIS Plus Investigators. Acute coronary syndromes in young patients: presentation, treatment and outcome. Int J Cardiol. 2011;148:300-304.
2. Reibis R, Treszl A, Wegscheider K, Bestehorn K, Karmann B, Völler H. Disparity in risk factor pattern in premature versus late-onset coronary artery disease: a survey of 15,381 patients. Vasc Health Risk Manag. 2012;8:473-481.
3. Risgaard B, Winkel BG, Jabbari R, et al. Burden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in Denmark. Circ Arrhythm Electrophysiol. 2014;7:205-211.
4. Khawaja FJ, Rihal CS, Lennon RJ, Holmes DR, Prasad A. Temporal trends (over 30 years), clinical characteristics, outcomes, and gender in patients p50 years of age having percutaneous coronary intervention. Am J Cardiol. 2011;107:668-674.
5. Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635-1701.
6. Paixao ARM, Enriquez JR, Wang TY, et al. Risk factor burden and control at the time of admission in patients with acute myocardial infarction: results from the NCDR. Am Heart J. 2015;170:173-179.e1.
7. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636-648.
8. The Danish National Institute of Public Health. The Danish Health and Morbidity Survey 2005 [Internet]; 2006 [cited October 23, 2015]:1-72. Available from: http://si-folkesundhed.dk/upload/personligt_interviewskema_ med_svarfordeling_-_2005.pdf. Accessed October 23, 2015.
9. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Family Pract. 2012;29:376-382.
10. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480.
11. Akesson A, Weismayer C, Newby PK, Wolk A. Combined effect of lowrisk dietary and lifestyle behaviors in primary prevention of myocardial infarction in females. Arch Intern Med. 2007;167:2122-2127.
12. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307:1273-1283.
13. Akesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the primary prevention of myocardial Infarction in males: a population-based prospective cohort study. J Am Coll Cardiol. 2014;64:1299-1306.
14. Farkouh ME, Boden WE, Bittner V, et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013;61:1607-1615.
15. Tully L, Gianos E, Vani A, et al. Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention. Am Heart J. 2014;168:310-316.e3.
16. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
17. Blood Pressure Lowering Treatment Trialists' Collaboration, Sundström J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591-598.
18. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, et al. ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC/ EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217 (Suppl 1):S1-44.
19. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012-1022.
20. Mancini GBJ, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29(12):1553-1568.
21. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158: 526-534.
22. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431-438.
23. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
24. Ciccone MM, Scicchitano P, Cameli M, et al. Endothelial function in pre-diabetes, diabetes and diabetic cardiomyopathy: a review. J Diabetes Metab. 2014;5:1-10.
25. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health. 2007;7:220.